Introduction
TNFa is known to be a potent mediator of in¯ammation and bone resorption. Bone barrow mononuclear cells (BMMCs), as well as plasma cells isolated from multiple myeloma (MM) patients, express TNFa mRNA and protein (Garrett et al., 1987; Lichtenstein et al., 1989; Filella et al., 1996; Sati et al., 1999) . Moreover, TNFa secretion in BM culture supernatants was signi®cantly higher in patients with bone disease than in patients without bone disease . To date, however, the direct eects of TNFa on MM cell growth and survival are not fully characterized. This is of particular interest due to the recent remarkable clinical responses in MM patients treated with thalidomide (Singhal et al., 1999) , which is known to inhibit TNFa, and our recent demonstration of the direct action of thalidomide on MM cells .
Additional interest in studying TNFa stems from its potential impact on paracrine MM cell growth and survival in the BM millieu. We Urashima et al., 1997; Chauhan et al., 1997 Chauhan et al., , 2000 and others (Akira et al., 1990; Lichtenstein et al., 1995; Catlett-Falcone et al., 1999) have reported that IL-6 both induces proliferation of MM cells, mediated via the mitogen activated protein kinase (MAPK) cascade, and confers protection against dexamethasone (Dex)-induced apoptosis of MM cells, via speci®c activation of protein tyrosine phosphatase (SHP2). Others have shown that adhesion of MM cells to bone marrow stromal cells (BMSCs) confers protection against drug-induced apoptosis (Damiano et al., 1999) , and we have shown that adherence of MM cells to BMSCs induces NF-kB dependent IL-6 transcription and secretion by BMSCs . To date, however, regulation of TNFa secretion by either MM cells or BMSCs alone, or by tumor cells bound to BMSCs, has not been characterized. Since there is a TNFa response element in the IL-6 promoter (Ray et al., 1989) , the indirect eects of TNFa mediated via IL-6 are also of great interest. Finally, TNFa is known to induce NF-kB-dependent expression of adhesion molecules (Palombella et al., 1998; Li et al., 2000) , further supporting its potential role in altering binding of MM cells to BMSCs within the BM millieu.
In this study, we show that TNFa induces a modest increase in proliferation, as well as MAPK/ERK activation, in MM cells. It induces IL-6 secretion, as well as NF-kB activation, in BMSCs. Importantly TNFa induces adhesion molecules on MM cells and BMSCs, with resultant increased MM cell to BMSC binding and IL-6 secretion; conversely, blockade of TNFainduced NF-kB activation inhibits these sequelae. These studies con®rm a central role for TNFa in the growth and survival of MM cells in the BM millieu and suggest the utility of novel therapeutics targeting TNFa in MM.
Results
TNFa secretion from IM-9 MM cells stimulates IL-6 secretion from BMSCs
We ®rst measured TNFa in culture supernatants of IM-9 MM cells alone, BMSCs alone, and IM-9 MM cells adherent to BMSCs. As can be seen Figure 1a , IM-9 cells secreted 30 and 72 pg/ml of TNFa in 24 and 48 h cultures, respectively, whereas BMSCs alone did not produce TNFa. Adhesion of IM-9 MM cells to BMSCs did not signi®cantly augment TNFa secretion above that noted by IM-9 cells alone. Low levels of IL-6 are secreted by BMSCs, but not IM-9 cells; as in our prior studies (Uchiyama et al., 1993; Chauhan et al., 1996) , adhesion of IM-9 cells to BMSCs signi®cantly increased IL-6 secretion ( Figure 1b) . Similar results were observed in MM.1S cells (data not shown).
To determine whether TNFa stimulates IL-6 secretion from BMSCs, we cultured BMSCs with TNFa for 48 h; VEGF and TGFb1 were used as positive controls for induction of IL-6 (Dankar et al., 2000; Junn et al., 2000) . As can be seen in Figure 1c , TNFa induced signi®cant (16-fold, P50.001) increases in IL-6 secretion in BMSCs, whereas VEGF and TGFb1 triggered only 2 ± 3-fold increases in IL-6 secretion. Finally, a dose-dependent eect of TNFa on IL-6 secretion was demonstrated when BMSCs from two MM patients were incubated with TNFa (0.0001 ± 10 ng/ml) ( Figure  1d ).
TNFa induces proliferation, NF-kB and p44/42 MAPK activation in MM.1S cells
We next examined the direct eect of TNFa on proliferation and signal transduction in MM.1S cells. Like IL-6 , TNFa (0.0016 ± 10 ng/ml) induced modest (5twofold) increase in [ 3 H]TdR incorporation (n=3, P=0.017 ± 0.035, respectively) and viable cell number, which was blocked by the MEK1 inhibitor PD098059 (Figure 2a ). Degradation of IkBa was also triggered by treatment of MM.1S cells with TNFa (Figure 2b) , and TNFa-induced NFkB activation in MM.1S cells was further con®rmed Since we Ogata et al., 1997; Urashima et al., 1997) and others (Borset et al., 1994; Catlett-Falcone et al., 1999) have shown that activation of p44/42 MAPK and STAT3 play role in cell proliferation and survival, respectively, in MM cells, we next examined whether TNFa triggered activation of p44/42 MAPK or STAT3 in MM.1S cells. As can be seen in Figure 2d , TNFa triggered phosphorylation of p44/42 MAPK, but not STAT3, in MM.1S cells. IL-6, which is known to activate MAPK and STAT3 in MM cells, was used as a positive control for activation of these kinases Catlett-Falcone et al., 1999) .
TNFa induces NF-kB and p44/42 MAPK activation in BMSCs
We similarly examined the eect of TNFa on proliferation and signal transduction in BMSCs. As can be seen in Figure 3a , TNFa (0.1 ± 10 ng/ml) for 48 h did not augment proliferation in BMSCs, assessed by MTT assay. However, EMSA demonstrated that TNFa treatment of BMSCs for 10 and 20 min activated NF-kB ( Figure 3b ). Importantly, this activation of NF-kB triggered by TNFa was inhibited by pre-treatment with proteasome inhibitor PS-341 (5 mM for 1 h). Finally, TNFa induced phosphorylation of p44/42 MAPK (Figure 3c ), but not of STAT3 (data not shown) in MM.1S cells.
TNFa induces adhesion molecules on MM cell lines
We next determined whether TNFa induces adhesion molecules on MM cells. MM.1S, RPMI-8226 and IM-9 MM cells were examined for CD11a (LFA-1), CD49d (VLA-4), CD54 (ICAM-1), and CD106 (VCAM-1) expression using immuno¯uorescence¯ow cytometry before and after treatment with TNFa. As can be seen in Table 1 , TNFa (10 ng/ml for 24 h) enhanced expression of CD11a, CD49d, and CD54, but not CD106, on both MM.1S cells and RPMI-8226 cells. Similar results were obtained in IM-9 cells (data not shown). This induction of CD11a, CD49d and CD54 expression on MM.1S cells occurred in a timedependent fashion (Table 2) . Culture with proteasome inhibitor PS-341 (Palombella et al., 1998) blocked TNFa-induced upregulation of CD54 (ICAM-1) expression on RPMI-8226 cells (Figure 4 ), as well as on MM.1S cells (data not shown).
TNFa induces CD54 (ICAM-1) and (CD106) VCAM-1 in BMSCs
We similarly determined whether TNFa induces adhesion molecules on BMSCs. Speci®cally, BMSCs were incubated for 2, 4 and 8 h in the presence TNFa (10 ng/ml), and the expression of ICAM-1 and VCAM-1 assessed by Western blotting. As can be seen in Figure 5a , expression of ICAM-1 and VCAM-1 was maximally induced after culture with TNFa for 2 h. Incubation of BMSCs with TNFa (0.4 ± 50 ng/ml) for 2 h demonstrated that induction of both ICAM-1 and VCAM-1 on BMSCs was TNFa dose-dependent ( Figure 5b ).
TNFa augments of adherence of MM.1S cells to BMSCs
Having shown that TNFa induces adhesion molecules on both MM cells and BMSCs, we next examined whether MM cell to BMSC binding was also increased. BMSCs from three MM patients were pre-treated with DMSO or TNFa to induce ICAM-1 and VCAM-1 expression, and MM.1S binding to these BMSCs was assessed as in prior studies (Uchiyama et al., 1993) . As can be seen in Figure 6 , TNFa triggered a dosedependent signi®cant increase (2.2 ± 4.5-fold, P50.01) in per cent speci®c binding of MM.1S cells to BMSCs. Electrophoretic mobility shift assay using nuclear extract from BMSCs was performed as described in Materials and methods. BMSCs cells were pre-treated with either DMSO control or PS-341 (5 mM for 1 h) prior to stimulation with TNFa (10 ng/ml) for indicated intervals. Nuclear extracts from BMSCs were immunoblotted with anti-p65 NF-kB Ab. (c) BMSCs were stimulated with TNFa (10 ng/ml). Whole lysates at dierent intervals were immunoblotted with anti-phospho-MAPK or ERK1 Abs
Adhesion of MM.1S cells induces p44/42 MAPK activation in BMSCs
We next examined whether adhesion of MM.1S cells could activate p44/42 MAPK in BMSCs. Although constitutive activation of both MEK1/2 and p44/42 MAPK in BMSCs was observed, maximal induction of MEK1/2 and p44/42 MAPK phosphorylation occurred after adhesion of 1% formaldehyde-®xed MM.1S cells for 10 min (Figure 7 ). IL-6 did not activate MAPK activity in formaldehyde-®xed MM.1S cells, con®rming that the adhesion-induced MAPK activation was in BMSCs.
Mechanism of TNFa-induced increased binding of MM.1S cells to BMSCs
To determine whether TNFa induced ICAM-1 and VCAM-1 expression on BMSCs via activation of NFkB, we next examined the eect of the proteasome inhibitor PS-341 on induction of these adhesion molecules. As seen in Figure 8a , pre-treatment of BMSCs with PS-341 (5 mM for 1 h), but not DMSO, abrogated induction of ICAM-1 or VCAM-1 by TNFa.
To con®rm the mechanism of increased MM.1S binding to BMSCs induced by TNFa, we next examined whether anti-ICAM-1 Ab, anti-VCAM-1 Ab, or PS-341 could block the augmentation of MM.1S cell to BMSC adhesion triggered by TNFa. PS-341 completely, whereas anti-ICAM-1 and/or anti-VCAM-1 Abs partially, abrogated the increased adhesion of MM.1S cells to BMSCs triggered by TNFa (Figure 8b ).
Discussion
TNFa is an in¯ammatory and bone resorbing cytokine with both direct and indirect eects mediated by induction of other cytokines. Previous reports of low levels of TNFa mRNA and protein in MM patient samples (Sati et al., 1999; Davies et al., 2000) , coupled with responses after treatment of MM patients with thalidomide (Singhal et al., 1999) and its known TNFa inhibitory activity (Corral et al., 1999) , provided the impetus for the current study to delineate the role of TNFa in the pathogenesis of MM. Although the direct eect of TNFa on MM cell proliferation is modest, it mediates two major eects in the BM to promote growth and survival of MM cells: direct stimulation of IL-6 production in BMSCs; and upregulation of adhesion molecules on MM cells and on BMSCs, thereby enhancing binding of MM cells to BMSCs and related IL-6 secretion. These studies highlight the importance of studying the MM cell within the BM millieu, and suggest TNFa as a novel therapeutic target in MM. Previous reports have detected TNFa mRNA and protein in six of 10 MM patients (Sati et al., 1999) , and demonstrated that TNFa induces in vitro proliferation of a MM cell line (Jourdan et al., 1999) . Our ®ndings also suggest that TNFa is secreted by MM cells, but that it is not a major MM growth factor. Our Chauhan et al., 1997 Chauhan et al., , 2000 Hideshima et al., 2000) and other (Borset et al., 1994; Lichtenstein et al., 1995; Catlett-Falcone et al., 1999) studies have demonstrated that IL-6 is the major growth and survival factor for human MM cells, and speci®cally shown that proliferation induced by IL-6 is mediated via the MAPK signaling pathway . The current study shows that TNFa-induced MM cell proliferation is also mediated via this cascade. There appear to be dierences, however, since IL-6 triggers STAT3 activation whereas TNFa does not. Importantly, there is known to be a TNFa response element in the IL-6 promoter (Ray et al., 1989) , and we show that TNFa markedly up-regulates IL-6 secretion in BMSCs. We have previously shown that TGFb secreted by MM cells augments IL-6 secretion in BMSCs , but the induction of IL-6 in BMSCs by TNFa observed in this study is much greater. Therefore one key role for TNFa in MM is to augment paracrine IL-6 mediated MM cell growth and survival.
We have shown that adherence of MM cells to MM patient BMSCs triggers IL-6 secretion from BMSCs via activation of NF-kB . Moreover, adherence of MM cells to BMSCs protects MM cells against drug-induced apoptosis (Damiano et al., 1999) . These reports con®rm the critical role of interactions between MM cells and BMSCs in the BM microenvironment. In our previous studies, we have delineated those adhesion molecules on MM cells (CD49d, VLA-4; CD11a, LFA-1; Muc-1) mediating adherence to extracellular matrix proteins (®bronectin) and to BMSCs (CD54, ICAM-1; CD106, VCAM-1) (Uchiyama et al., 1992 (Uchiyama et al., , 1993 Kim et al., 1994; Teoh and Anderson, 1997) . Moreover, TNFa induces VCAM-1 and ICAM-1 expression in a NF-kB dependent manner in human umbilical vein endothelial (HUVE) cells (Palombella et al., 1998) . In the present study, we demonstrate that TNFa induces adhesion molecules on both MM cells (CD49d, VLA4; CD11a, LFA-1; Muc-1) and BMSCs (CD54, ICAM-1; CD106, VCAM-1), which results in increased MM cell to BMSC adhesion (Figure 9 ). Increased tumor cell binding in turn induces IL-6 secretion from MM patient BMSCs. Our recent studies further suggest that vascular endothelial growth factor (VEGF) is secreted by MM cells, and that this secretion is also markedly upregulated by MM cell adhesion to BMSCs ). VEGF may not only account for the increase in MM BM angiogenesis, but our studies further demonstrate that VEGF directly acts on MM cells to trigger migration . Therefore inhibition of increased adhesion triggered by TNFa will likely inhibit not only growth and survival eects of adhesion, but also tumor cell migration.
We have previously shown that the proteasome inhibitor PS-341 directly induces apoptosis even of MM cells resistant to conventional therapy, and downregulates the NF-kB dependent induction of IL-6 in BMSCs triggered by MM cell binding . Since PS-341 has previously been reported to inhibit TNFa-induced ICAM-1, VCAM-1, or ESelectin expression on HUVE cells (Palombella et al., 1998) , we assessed whether it acted similarly in MM. Speci®cally, we show that PS-341 abrogates TNFainduced upregulation of adhesion molecules on both MM cells and BMSCs and, most importantly, inhibits MM cell to BMSC binding. This blockade both further validates strategies to target TNFa in MM and has important implications for other novel treatment approaches in MM. For example, thalidomide has recently been used to achieve responses in MM refractory to conventional therapy (Singhal et al., 1999) , based upon its anti-angiogenic activity (D'Amato et al., 1994) and the increased angiogenesis observed in MM BM (Vacca et al., 1999) . However, we have recently shown that thalidomide and its immunomodulatory derivatives have multiple anti-MM activities: direct action on MM cells to induce apoptosis or G1 growth arrest; blockade of the increased secretion of MM cell growth, survival, and migration factors (IL-6, VEGF) triggered by binding of MM cells to BMSCs; expansion of patients' natural killer cell number and function against MM cells; and downregulation of protectin expression in MM cells (Raje and Anderson, 1999; Hideshima et al., 2000; Treon et al., 2001; Davies et al., 2001) . Although both thalidomide and the immunomodulatory derivatives inhibit TNFa production from LPS-stimulated monocytes (Marriott et al., 1998) , they also inhibit IL-1b and IL-6 and increase IL-10 production in these cells (Corral et al., 1999) ; stimulate T-cell proliferation, IL-2, and interferon-g production (Haslett et al., 1998) ; and do not inhibit phosphodiesterase-4. Characterization of these independent bioactivities of TNFa on MM cells in the BM millieu will not only aid in determining which of these multiple activities of thalidomide and the immunomodulatory drugs is clinically relevant, but also may allow for the development of novel therapeutics with increased ecacy and decreased toxicity.
The current study therefore demonstrates important eects mediated by TNFa on MM cell growth, survival, and migration which would not have been appreciated if MM cells were examined alone and only became apparent when studying MM cells in the context of the BM millieu. These studies therefore con®rm the importance of evaluating new agents not only for their direct anti-tumor eects, but also for their impact on intercellular interactions and cytokine production within the BM. Importantly, these studies provide a strong rationale for targeting TNFa in novel therapeutics in MM.
Materials and methods

Cell cultures
MM.1S cells were kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA). The cells were cultured in RPMI-1640 media containing 10% fetal bovine serum (FBS, Sigma Chemical Co., St. Louis, MO, USA), 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (GIBCO, Grand Island, NY, USA). BM specimens were obtained from patients with MM with appropriate Institutional Review Board approval. Mononuclear cells (MNCs) separated by Ficoll-Hypaque density sedimentation were used to establish long-term BMSC cultures, as previously described (Uchiyama et al., 1993) . When an adherent cell monolayer had developed, BMSCs were harvested in Hank's Buered Saline Solution containing 0.25% trypsin and 0.02% EDTA, washed, and collected by centrifugation.
Measurement of TNFa and IL-6
Both TNFa and IL-6 were measured in cell supernatants using Duoset ELISA (R&D System, Minneapolis, MN, USA). To examine whether adherence of IM-9 MM cells to BMSCs induces TNFa and IL-6 secretion from BMSCs, BMSCs were incubated with or without IM-9 cells and culture supernatants harvested at 24 or 48 h. BMSCs were also incubated in the presence of VEGF (10 ng/ml), TNFa (10 ng/ml) or TGFb1 (10 ng/ml) for 24 h to similarly assay for induction of TNFa and IL-6 secretion.
Cell proliferation
Colorometric assays were performed to assess the eect of TNFa on proliferation of BMSCs, as in prior studies . Cells from 48 h cultures of BMSCs TNFa in multiple myeloma T Hideshima et al were pulsed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT, Chemicon International Inc., Temecula, CA, USA) for 4 h (10 ml of 5 mg/ml per well), followed by 100 ml isopropanol containing 0.04N HCl. Absorbance readings at 570 nm were measured on a spectrophotometer (Molecular Devices Corp., Sunnyvale, CA, USA). Tritiated thymidine incorporation assays ([ 3 H]TdR) were also performed to assess cell proliferation, as previously described . Viable cells were enumerated using Trypan blue exclusion.
Western blotting
ICAM-1 or VCAM-1 expression in BMSCs was assayed by Western blotting. BMSCs were incubated in the presence of 10 ng/ml human recombinant TNFa (R&D System) at 378C for 2, 4 and 8 h. To assay for dose dependency, BMSCs were incubated for 4 h in the presence of TNFa (0.2 to 50 ng/ml). The cells were lysed in lysis buer: 50 mM TrisHCl (pH 7.4), 150 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM NaF, 2 mM Na 3 VO 4 , 1 mM PMSF, 5 mg/ml leupeptine, 5 mg/ml aprotinin. For detection of ICAM-1, VCAM-1, and phosphorylated MAPK, cell lysates were subjected to SDS ± PAGE, transferred to PVDF membranes (Bio-Rad Laboratories, Hercules, CA, USA), and immunoblotted with anti-ICAM-1, anti-VCAM-1 (Santa Cruz Biotech., Santa Cruz, CA, USA), and anti-phospho MAPK (New England Biolabs, Beverly, MA, USA) Abs, respectively. Immunoblotting with anti-alpha-tubulin Ab (Sigma) con®rmed equivalent protein loading. Similar immunoblotting was performed on BMSCs pre-treated with proteasome inhibitor PS-341 (10 mM, Millennium Pharmaceuticals Inc., Cambridge, MA, USA) for 1 h prior to incubation with TNFa (10 ng/ml) for 2 h.
Flow cytometric analysis
MM.1S, RPMI-8226, and IM-9 cells were cultured for 24 h in the presence or absence of TNFa (10 ng/ml), washed, and stained with speci®c Abs directed against CD11a (LFA-1), CD49d (VLA-4), CD54 (ICAM) (Immunotech, Marseille, France), CD106 (VCAM) (R&D System, Minneapolis, MN, USA) in either direct (CD11a, CD49d and CD54) or indirect (CD106) immuno¯uorescence assays and¯ow cytometric analysis, as previously described (Uchiyama et al., 1992) .
Adhesion assays
Assays of adherence of MM cells to BMSCs were performed as previously described (Uchiyama et al., 1993) . MM.1S cells labeled with Na 2 CrO 4 (NEN, Boston, MA, USA), were added to either TNFa pre-treated (10 ng/ml for 2 h) or nontreated BMSC-coated 96-well plates and incubated for 1 h. After incubation, each well was washed twice with media and lysed with 0.5% NP-40; lysate radioactivity was counted on a gamma counter. The proteasome inhibitor PS-341, anti-ICAM-1 Ab, and/or anti-VCAM-1 Ab (R&D System) were used to block TNFa-induced augmentation of adhesion. Speci®cally, BMSCs were pre-treated with either DMSO (0.1%) or PS-341 (10 mM) before stimulation with TNFa (10 ng/ml) for 2 h and MM cell adhesion. TNFa-stimulated BMSCs were incubated with anti-ICAM-1 Ab and/or anti- 
Assays for activation of NF-kB
To assay for NF-kB activation in BMSCs, BMSCs were preincubated with PS-341 (10 mM for 1 h) before stimulation with TNFa (10 ng/ml for 10, 20 or 30 min). Degradation of IkBa was used to assay for activation of NF-kB in MM cells (Palombella et al., 1998) . To analyse the eect of TNFa on degradation of IkBa in MM.1S cells, the cells were incubated with TNFa (5 ng/ml), washed, and lysed. Whole cell extracts were prepared and analysed by Western blotting with antiIkBa Ab (Santa Cruz Biotech.)
Electrophoretic mobility shift analysis
Nuclear extracts for electrophoretic mobility shift analyses (EMSA) were carried out as in our previous studies . Brie¯y, double-stranded NF-kB consensus oligonucleotide probe (5' -GGGGACTTTCCC-3', Santa Cruz Biotech.) was end-labeled with g 32 P-ATP (50 mCi at 222 TBq/mM; NEN, Boston, MA, USA). Binding reactions containing 1 ng of oligonucleotide and 3 mg of nuclear protein were conducted at room temperature for 20 min in total volume of 10 ml of binding buer [(10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM DTT, 4% glycerol (v/v), and 0.5 mg poly (dI-dC) (Pharmacia, Peapack, NJ, USA)]. For supershift analysis, 1 mg of anti-p65 NF-kB Ab (Santa Cruz Biotech.) was added 5 min before the reaction mixtures, immediately after addition of radiolabeled probe. The samples were loaded onto a 4% polyacrylamide gel, transferred to Whatman paper (Whatman International, Maidstone, UK), and visualized by autoradiography.
Assay for MAPK signaling in BMSCs triggered by MM cell adhesion
BMSCs were cultured overnight in ISCOVE's MEM supplemented with 2% FBS (2% ± ISCOVE), washed twice, and re-suspended in 2% ± ISCOVE. BMSCs were subsequently incubated with TNFa (10 ng/ml) for 2 h and washed two times with 2% ± ISCOVE. MM.1S cells were ®xed in 1% paraformaldehyde (48C for 40 min), washed three times with PBS, resuspended in 2% ± ISCOVE, and then added to TNFa pre-pretreated BMSCs. After incubation for 10, 20 or 30 min, the cells were scraped, washed, lysed, and immunoblotted to detect tyrosine phosphorylated P44/42 MAPK and serine phosphorylated MEK1/2 with anti-phospho MAPK and antiphospho MEK1/2 Abs, respectively (New England Biolabs).
